A South Korean life sciences company plans to open a genetic testing lab in North Austin, a move that could create up to 200 ...
New peptide research blend shows promise as a game-changer in the fitness space BURTON, MI, UNITED STATES, January 19, ...
They work inside integrated development environments (IDEs), where code, documentation, testing, version history and ...
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best medical research stocks to buy according to hedge funds. On February 11, BofA lifted the price target on Gilead Sciences, Inc. (NASDAQ:GILD) to ...
Before you buy stock in Gilead Sciences, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Gilead ...
Zacks Investment Research on MSN
Exact Sciences (EXAS) reports Q4 loss, tops revenue estimates
Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of breakeven. This compares to a loss of $0.06 per share a year ago. These figures are ...
Students, young professionals, and industry leaders invited to explore emerging GIS trends and network with innovators ...
Roivant saw its share prices jump by 19.4 percent week-on-week, hitting a new all-time high, as investors snapped up shares ...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025.
Dr. Cindi Love, Executive Director of Out for Undergrad, emphasized the significance of Valladares’ appointment: ...
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results